Welcome to our dedicated page for Repligen news (Ticker: $RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Repligen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Repligen's position in the market.
Repligen (NASDAQ:RGEN) will attend several investor conferences in May, including RBC Capital Markets' Global Healthcare Conference in New York, Craig-Hallum's Institutional Investor Conference in Minneapolis, and Leerink Partners' Healthcare Crossroads Conference in Austin. Jason K. Garland, Chief Financial Officer, will participate in analyst-led discussions and one-on-one meetings with investors at each event. Live webcasts of the RBC and Leerink presentations will be accessible via Repligen's Investor Relations website.
Repligen reported first quarter revenue of $151 million, a 16% increase in new modalities revenue, and a 12% increase in Filtration (non-COVID) revenue year-over-year. The company achieved a nine-month book-to-bill ratio of 1.03. Financial performance in Q1 2024 saw a decline in reported revenue and gross profit compared to Q1 2023, primarily due to COVID-related revenue absence and a decline in Proteins revenue. Adjusted figures showed a decrease in income from operations and net income. Cash, cash equivalents, and short-term investments at the end of Q1 2024 were $780.6 million. Repligen reiterated its financial guidance for full year 2024, expecting orders to pick up in the second half of the year. The company's adjusted financial guidance for FY 2024 remains unchanged, with total reported revenue expected to be in the range of $620M - $650M.
